Our previous studies also showed that cytokines over-produced in IBD, such as TNF-α, can enhance the production of IL-34 and, consistently, the neutralization of TNF with infliximab, a TNF blocker, reduced IL-34 production in IBD LPMC cultures, and in vivo in IBD patients [9]. This evidence concerns the gene TNF and inflammatory bowel disease.